The therapeutic potential of GLP‐1 receptor biased agonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments for type 2 diabetes as they stimulate insulin release and promote weight loss through appetite suppression. Their main side effect is nausea. All approved GLP‐1 agonists are full agonists across multiple signalling pathways. However, selective engagement with specific intracellular effectors, or biased agonism, has been touted as a means to improve GLP‐1 agonists therapeutic efficacy. In this review, I critically examine how GLP‐1 receptor‐mediated intracellular signalling is linked to physiological responses and discuss the implications of recent studies investigating the metabolic effects of biased GLP‐1 agonists. Overall, there is little conclusive evidence that beneficial and adverse effects of GLP‐1 agonists are attributable to distinct, nonoverlapping signalling pathways. Instead, G protein‐biased GLP‐1 agonists appear to achieve enhanced anti‐hyperglycaemic efficacy by avoiding GLP‐1 receptor desensitisation and downregulation, partly via reduced β‐arrestin recruitment. This effect seemingly applies more to insulin release than to appetite regulation and nausea, possible reasons for which are discussed. At present, most evidence derives from cellular and animal studies, and more human data are required to determine whether this approach represents a genuine therapeutic advance. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 2×
“GLP-1 agonist treat- ment improves glycaemia, aids weight loss, improves cardiovascular, renal and limb outcomes, and leads to a reduction in all-cause mortality in type 2 diabetes (Kristensen et al., 2019; Zheng et al., 2018).”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“2022;179:492–510.wileyonlinelibrary.com/journal/bph also effective in causing weight loss in people without type 2 diabetes (Davies et al., 2015) and for non-alcoholic fatty liver disease (Armstrong et al., 2016).”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“Previous concerns have been raised about the potential for GLP-1 agonists to cause pancreatitis (Garber et al., 2009), although this has not been confirmed in recent analyses (Storgaard et al., 2017).”
ResultThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 2×
“Early work confirmed GLP-1 stimulates cAMP production in islet cell lines and the brain (Drucker et al., 1987; Shimizu et al., 1987).”
BackgroundCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“Initial descriptions of tirzepatide showed similar GIPR potency to native GIP but fivefold reduced potency for GLP-1 receptor (Coskun et al., 2018).”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 2×
“…of opioid medications are G protein-mediated but respiratory depression depends on specific β-arrestin-dependent signalling (Raehal et al., 2005; Schmid et al., 2017), although this has recently been chal- lenged through re-evaluation of the bias profiles of purportedly biased μ agonists…”
BackgroundGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 1×
“In particular, GLP-1 receptor is highly expressed in beta cells but at much lower levels in neurons and other tissues (Richards et al., 2014).”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · cited 1×
“Even though tirzepatide is a potent activator of GIP receptor, the contribution of GIP receptor to its overall metabolic effects is not fully understood, although effects on adipose tissue are probably important (Samms et al., 2020).”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“The effect of GLP-1 on gastric emptying undergoes rapid tachyphylaxis (Nauck et al., 2011) and this observation has been used to support the use of “short-acting” GLP-1 agonists that allow a between-dose re-sensitisation period and restora- tion of the beneficial effects of gastric emptying on…”
MethodBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 2×
“…al., 2018), although it is difficult to ascribe this to biased GLP-1 receptor agonism due to the potential for GIPR-induced appetite sup- pression (Adriaenssens et al., 2019) and the fact that the large molec- ular size of dulaglutide may limit access to appetite regulatory centres to a greater…”
BackgroundAmbery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J.-C., & Olefsky, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710402105 · Cited by 239
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
Wheeler, M. B., Lu, M., Dillon, J. S., Leng, X. H., Chen, C., & Boyd, A. E. (1993) · Endocrinology · doi:10.1210/endo.133.1.8391428 · Cited by 225
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 1×
“Real-world experience suggests the extent of the problem may not be fully represented in clinical trials (Sikirica et al., 2017).”
BackgroundGlucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
Lipotoxicity disrupts incretin-regulated human β cell connectivity
Hodson, D. J., Mitchell, R. K., Bellomo, E. A., Sun, G., Vinet, L., Meda, P., Li, D., Li, W.-H., Bugliani, M., Marchetti, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68459 · Cited by 210
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
The dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194 · cited 1×
“There is emerging evidence for other beneficial actions of GLP-1 agonists, including preservation of pancreatic beta cell mass (Boland et al., 2017), protection against neurodegenerative processes including Alzheimer's and Parkinson's disease (Grieco et al., 2019) and treatment of mood disorders…”
BackgroundGLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189 · cited 3×
“In the latter study, both efficacy and potency were higher for Gαs than for Gαq, with some evidence of coupling to Gαi also demonstrated.”
BackgroundStorgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling
Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149 · cited 1×
“Pharmacological inhibi- tion of ERK1/2 also abrogated the effects of GLP-1 agonists on neu- ronal survival (Zhu et al., 2016), adipocyte differentiation (Challa et al., 2012) and osteogenic precursor proliferation (Wu et al., 2017).”
BackgroundGromada, J., Ding, W.-G., Barg, S., Renström, E., & Rorsman, P. (1997) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050431 · Cited by 110 · cited 1×
“PKA phosphorylates multiple targets involved in intracellular Ca2+ homeostasis, such as KATP channels that control membrane depolarisation (Gromada et al., 1997) and inositol triphosphate receptors that promote release of Ca2+ from intracellular stores (Tsuboi et al., 2003).”
BackgroundKim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109 · cited 1×
“…evidence for other beneficial actions of GLP-1 agonists, including preservation of pancreatic beta cell mass (Boland et al., 2017), protection against neurodegenerative processes including Alzheimer's and Parkinson's disease (Grieco et al., 2019) and treatment of mood disorders (Kim et al., 2020).”
BackgroundWu, X., Li, S., Xue, P., & Li, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.018 · Cited by 92
Kaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B. (2013) · Diabetes · doi:10.2337/db12-1013 · Cited by 80 · cited 1×
“…of evidence, including by observing the effects of pharmacological PKA inhibition (Skoglund et al., 2000), genetic manipulation of PKA activity (Kaihara et al., 2013) and inter- ference with the correct localisation of PKA by disrupting A-kinase anchoring proteins (AKAPs) (Lester et al.,…”
BackgroundSassmann, A., Gier, B., Gröne, H.-J., Drews, G., Offermanns, S., & Wettschureck, N. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41541 · Cited by 75
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001706 · Cited by 71 · cited 1×
“Monitoring acute reductions in food intake may be an approximate surrogate of nausea in mice, although the lack of an association between gastro-intestinal adverse effects and weight loss in GLP-1 agonist clinical trials suggest different mechanisms may be involved in humans (Lingvay et al., 2020).”
BackgroundDzhura, I., Chepurny, O. G., Kelley, G. G., Leech, C. A., Roe, M. W., Dzhura, E., Afshari, P., Malik, S., Rindler, M. J., Xu, X., et al. (2010) · The Journal of Physiology · doi:10.1113/jphysiol.2010.198424 · Cited by 67 · cited 2×
“Epac2 is also involved in KATP channel closure (Kang et al., 2008), activation of PLC-ϵ (Dzhura et al., 2010) and acti- vation of ryanodine receptors (Tsuboi et al., 2003), all of which lead to Ca2+ elevations.”
BackgroundCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39 · cited 1×
“Investigation of nausea is challenging in mice due to the lack of an emesis response but can be performed using conditioned taste aver- sion or behavioural assays (Jones, Bloom, et al., 2018) or in other rodent species such as shrews (Borner et al., 2020).”
MethodFang, Z., Chen, S., Pickford, P., Broichhagen, J., Hodson, D. J., Corrêa, I. R., Kumar, S., Görlitz, F., Dunsby, C., French, P. M. W., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00022 · Cited by 38
Self-citationEffects of glucagon like-1(7–36)amide on the ctoplasmic Ca2+-concentration in rat islet cells
Fridolf, T., & Ahrén, B. (1993) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(93)90098-5 · Cited by 29
Research works printed but not linked: 105
- 10.1111/bph.14748 · DOI · Paper page
- 10.1111/bph.14751 · DOI · Paper page
- 10.1016/S0140-6736(15)00803-X · DOI · Paper page
- 10.1038/s41467-020-14309-w · DOI · Paper page
- Avet C. Mancini A. Breton B. Le Gouill C. Hauser A. S. Normand C. Kobayashi H. Gross F. Hogue M. Lukasheva V. &Morissette S.(2020).Selectivity Landscape of 100 Therapeutically Relevant GPCR Profiled by an Effector Translocation‐Based BRET Platform. bioRxiv48: 2020.04.20.052027. · DOI
- 10.1172/JCI126309 · DOI · Paper page
- 10.1002/path.5056 · DOI · Paper page
- 10.3390/biology9120473 · DOI
- 10.1126/scitranslmed.aan0972 · DOI · Paper page
- 10.2337/diabetes.52.4.974 · DOI · Paper page
- 10.1371/journal.pbio.3000097 · DOI · Paper page
- 10.1371/journal.pbio.1000172 · DOI · Paper page
- 10.1038/nm.3997 · DOI · Paper page
- 10.1002/cbic.201900300 · DOI
- 10.1038/s41596-018-0028-3 · DOI · Paper page
- 10.1124/jpet.110.166009 · DOI
- 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- 10.1083/jcb.131.1.69 · DOI · Paper page
- 10.1016/j.bcp.2020.114150 · DOI · Paper page
- 10.4161/cl.23967 · DOI · Paper page
- 10.3390/ijms21218404 · DOI · Paper page
- 10.1016/0026-0495(94)90132-5 · DOI
- 10.1016/j.bcp.2018.09.003 · DOI
- 10.1039/C9SC02079A · DOI
- Fridolf T., 1991, GLP‐1(7‐36) amide stimulates insulin secretion in rat islets: Studies on the mode of action, Diabetes Research, 16, 185
- 10.3389/fphys.2020.00555 · DOI · Paper page
- 10.1016/j.bcp.2016.03.003 · DOI
- 10.1126/scisignal.aaz3140 · DOI · Paper page
- 10.1016/j.tips.2020.09.009 · DOI · Paper page
- 10.1016/j.molmet.2017.08.002 · DOI · Paper page
- 10.1152/ajpgi.1989.257.3.G397 · DOI · Paper page
- Griffith D. A. Edmonds D. J. Fortin J. P. Kalgutkar A. S. Kuzmiski J. B. Loria P. M. Saxena A. R. Bagley S. W. Buckeridge C. Curto J. M. &Derksen D. R.(2020).A small‐molecule oral agonist of the human glucagon‐like peptide‐1 receptor. bioRxiv261: 2020.09.29.319483. · DOI
- 10.1038/s41467-017-02661-3 · DOI · Paper page
- 10.1016/j.bcp.2017.03.018 · DOI · Paper page
- 10.1021/jacs.6b08323 · DOI
- 10.1016/j.cmet.2011.02.001 · DOI · Paper page
- 10.1124/jpet.109.158519 · DOI
- 10.1016/j.peptides.2017.12.013 · DOI
- 10.1038/s41467-018-03941-2 · DOI · Paper page
- 10.1074/jbc.ra120.016334 · DOI · Paper page
- 10.1124/jpet.107.120006 · DOI
- 10.1113/jphysiol.2007.143818 · DOI · Paper page
- 10.1074/jbc.M108378200 · DOI · Paper page
- 10.1055/s-0030-1249035 · DOI
- 10.1038/srep41085 · DOI · Paper page
- 10.1124/mol.117.111187 · DOI
- 10.1021/cn200111m · DOI · Paper page
- 10.1111/j.1476-5381.1984.tb10753.x · DOI
- 10.1038/ncomms10842 · DOI · Paper page
- 10.1111/bph.15004 · DOI · Paper page
- 10.1124/mol.110.065664 · DOI · Paper page
- 10.1152/ajpendo.00551.2012 · DOI · Paper page
- 10.1073/pnas.94.26.14942 · DOI · Paper page
- 10.1021/jacs.9b05365 · DOI
- 10.1038/nature25773 · DOI · Paper page
- 10.1016/j.neuron.2017.09.042 · DOI · Paper page
- 10.1038/382083a0 · DOI · Paper page
- 10.1016/j.molmet.2020.100991 · DOI · Paper page
- 10.1073/pnas.041604898 · DOI · Paper page
- 10.1126/scisignal.aat7650 · DOI · Paper page
- 10.1016/j.coemr.2020.07.003 · DOI
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
- 10.1016/j.molmet.2021.101181 · DOI · Paper page
- 10.1172/JCI140046 · DOI · Paper page
- 10.1021/acssensors.9b01414 · DOI
- 10.1038/srep44247 · DOI
- 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
- 10.1016/j.ejphar.2020.173706 · DOI
- 10.1111/bph.15134 · DOI · Paper page
- 10.1016/j.ejmech.2016.10.044 · DOI
- 10.1021/acscentsci.7b00237 · DOI
- 10.1074/jbc.M109.067207 · DOI · Paper page
- 10.1124/jpet.105.087254 · DOI · Paper page
- 10.1007/s00125-013-3130-7 · DOI
- 10.2337/dc20-0190 · DOI · Paper page
- 10.1074/jbc.M114.592436 · DOI · Paper page
- 10.1186/s12575-019-0116-y · DOI
- 10.1210/endo-121-3-1076 · DOI · Paper page
- 10.1111/jdi.12900 · DOI
- 10.1172/JCI72434 · DOI · Paper page
- 10.2337/diabetes.49.7.1156 · DOI · Paper page
- 10.2337/db12-1394 · DOI · Paper page
- 10.1016/j.bcp.2014.10.015 · DOI
- 10.1111/dom.13494 · DOI · Paper page
- 10.1042/bj20021288 · DOI · Paper page
- 10.1021/acsptsci.0c00193 · DOI
- 10.1074/jbc.RA118.001975 · DOI · Paper page
- 10.1016/j.neuroscience.2012.09.025 · DOI
- 10.1111/bph.12716 · DOI · Paper page
- 10.1038/s41598-017-03486-2 · DOI
- 10.1042/bj3100203 · DOI · Paper page
- 10.1038/s41580-018-0049-3 · DOI · Paper page
- 10.1016/j.cell.2016.05.023 · DOI · Paper page
- 10.1124/jpet.110.176362 · DOI
- 10.1073/pnas.0704796104 · DOI · Paper page
- 10.1016/j.bcp.2020.114001 · DOI · Paper page
- 10.1016/j.cmet.2006.10.001 · DOI · Paper page
- 10.1016/0167-0115(93)90137-W · DOI
- 10.1038/ncomms9918 · DOI · Paper page
- 10.1016/j.ydbio.2009.12.042 · DOI
- 10.1016/j.molcel.2020.09.020 · DOI · Paper page
- 10.1038/s41586-019-1902-z · DOI · Paper page
- 10.1001/jama.2018.3024 · DOI · Paper page
- 10.1038/srep26859 · DOI · Paper page
- 10.1038/ncomms14295 · DOI · Paper page
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“One prevailing theory is that tirzepatide is an imbalanced and biased GLP-1 RA with very low ef fi cacy for recruitment of β -arrestin, whilst is acting as an unbiased GIP agonist with full ef fi cacy for β -arrestin recruitment [51, 52].”
Emerging Role of cAMP/AMPK Signaling
Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“While cursory efforts have been devoted to characterizing the structure activity relationship responsible for this signaling profile at the GLP-1R [65], the structural and sequence determinants of biased agonism at GIPR and GcgR are largely unknown, and thus would add another level of complexity to the structuree acti…”
BackgroundHorn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Gao, W., Liu, L., Huh, E., Gbahou, F., Cecon, E., Oshima, M., Houzé, L., Katsonis, P., Hegron, A., Fan, Z., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00889-6 · Cited by 56
“This observation supports the concept that β-arr-dependent internalization limits the action of GLP1R activation on insulin secretion and suggests that carriers of LoF variants not associated with β-arr could benefit from Gs-biased ligands 24 .”
Background
Metadata
- Authors
- Jones, B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-05-20
- Volume
- 179
- Issue
- 4
- Pages
- 492-510
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3156815314
- Cited by
- 98
- References
- 45
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Biotechnology and Biological Sciences Research Council
- European Foundation for the Study of Diabetes
- National Institute for Health Research
- Sunesis
- British Society for Neuroendocrinology
- Society for Endocrinology
- Engineering and Physical Sciences Research Council
- NIHR Imperial Biomedical Research Centre
- Academy of Medical Sciences
- Medical Research Council Canada (MR/R010676/1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.